Skip to main content

Amivantamab Dosage

Medically reviewed by Last updated on Jun 15, 2023.

Applies to the following strengths: vmjw 50 mg/mL

Usual Adult Dose for Non-Small Cell Lung Cancer

Weeks 1 to 4:

Week 5 onwards:

Duration of therapy: Until disease progression or unacceptable toxicity.

Infusion Rates for 1050 mg Dose:

Infusion Rates for 1400 mg Dose:


Use: For the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by US FDA-approved test, whose disease has progressed on/after platinum-based chemotherapy

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

Dose reductions for adverse reactions:

Dermatologic Adverse Reactions (including acneiform dermatitis, pruritus, dry skin):

Infusion-Related Reactions:

Interstitial Lung Disease (ILD)/Pneumonitis:
Any Grade:

Other Adverse Reactions:



Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.


Data not available

Other Comments

Administration advice:

Storage requirements:

Reconstitution/preparation techniques:

IV compatibility:



Patient advice:

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.